Alkemi
Alkemi specializes in launching breakthrough treatments and rare disease therapies by developing customized, step-by-step market access strategies called 'Breakthrough Blueprints'. They focus on transforming access into adoption quickly through their signature methodology, helping clients navigate market conditions and set strategic market access plans. Their approach involves designing market maps, developing high-impact hitlists, and deploying market shaping manuals to ensure rapid and effective treatment launches. Alkemi's team includes senior experts, research directors, and advisors with extensive experience in health economics, market access, and medical affairs. They have a strong focus on patient access, stakeholder communication, and evidence generation, with a mission to help clients get breakthrough treatments into the hands of patients efficiently.
Industries
Nr. of Employees
small (1-50)
Alkemi
Cambridge, Massachusetts, United States
Products
Whitepaper: Value in the Crosshairs (downloadable report)
A downloadable report examining value communication and market access challenges (available as a PDF report).
Access Threat Response System™
Delivers a realigned access plan in 90 days or less to protect commercial potential and investor confidence when facing payer pushback or stalled reimbursement.
Launch Shield™
Builds early visibility into reimbursement pathways and regulatory requirements for assets still in development, creating payer-ready strategies.
HEOR and Market Access Consulting Services
Consulting and advisory services designed to help life science, pharma, biotech, and medtech companies prove therapeutic value, accelerate market access, and navigate complex pricing and reimbursement strategies.
AMCP dossier
AMCP dossier articulating clinical and value evidence to payers.
Global Access Navigator
An integrated platform and digital navigator tool designed to centralize case studies, resources, guidance, and local access insights to coordinate global market access and launch readiness for life sciences and pharmaceutical companies.
Whitepaper: Value in the Crosshairs (downloadable report)
A downloadable report examining value communication and market access challenges (available as a PDF report).
Access Threat Response System™
Delivers a realigned access plan in 90 days or less to protect commercial potential and investor confidence when facing payer pushback or stalled reimbursement.
Launch Shield™
Builds early visibility into reimbursement pathways and regulatory requirements for assets still in development, creating payer-ready strategies.
HEOR and Market Access Consulting Services
Consulting and advisory services designed to help life science, pharma, biotech, and medtech companies prove therapeutic value, accelerate market access, and navigate complex pricing and reimbursement strategies.
AMCP dossier
AMCP dossier articulating clinical and value evidence to payers.
Global Access Navigator
An integrated platform and digital navigator tool designed to centralize case studies, resources, guidance, and local access insights to coordinate global market access and launch readiness for life sciences and pharmaceutical companies.
Services
Tailored, stepwise launch plans that combine market mapping, stakeholder prioritization, payer engagement, and execution support to accelerate access.
Design and execution of health economic analyses, budget impact models, and value dossiers to support reimbursement and formulary decisions.
Systematic literature reviews, medical writing, and preparation of peer-reviewed manuscripts and conference materials.
Programs to engage clinicians, payers, and guideline bodies to influence adoption, guideline inclusion, and formulary decisions.
Delivery of training sessions and adoption materials to prepare internal teams and external stakeholders for product rollout.
Tailored, stepwise launch plans that combine market mapping, stakeholder prioritization, payer engagement, and execution support to accelerate access.
Design and execution of health economic analyses, budget impact models, and value dossiers to support reimbursement and formulary decisions.
Systematic literature reviews, medical writing, and preparation of peer-reviewed manuscripts and conference materials.
Programs to engage clinicians, payers, and guideline bodies to influence adoption, guideline inclusion, and formulary decisions.
Delivery of training sessions and adoption materials to prepare internal teams and external stakeholders for product rollout.
Expertise Areas
- Market access strategy and commercialization
- Launch planning and market rollout
- Payer engagement and reimbursement strategy
- Health economics and outcomes research (HEOR)
Key Technologies
- Health economics modeling
- Budget impact analysis
- Systematic literature review
- Stakeholder mapping frameworks
News & Updates
Oncology Treatment Case Study
Unrestricted patient access & full payer coverage granted in 7 days, boosting company revenue by 140% and share price by 90% within 12 months.
Market Shaping Impact Study
Research on redefining patient journey in rare disease access, presented at ISPOR EU 2024.
Hospital Formulary Access Research
Economic evidence for pre-filled injectable medications published in European Journal of Hospital Pharmacy.
Documentation is essential for stakeholder communication, published in Journal of Evaluation in Clinical Practice.
Research highlighting the substantial budget impact, published in ASPH Mid-year 2024.
Market shaping impact study presented at ISPOR EU 2024.
Oncology Treatment Case Study
Unrestricted patient access & full payer coverage granted in 7 days, boosting company revenue by 140% and share price by 90% within 12 months.
Market Shaping Impact Study
Research on redefining patient journey in rare disease access, presented at ISPOR EU 2024.
Hospital Formulary Access Research
Economic evidence for pre-filled injectable medications published in European Journal of Hospital Pharmacy.
Documentation is essential for stakeholder communication, published in Journal of Evaluation in Clinical Practice.
Research highlighting the substantial budget impact, published in ASPH Mid-year 2024.
Market shaping impact study presented at ISPOR EU 2024.